

AWARD NUMBER: W81XWH-10-2-0121

TITLE: Hibernation-Based Therapy to Improve Survival of Severe Blood Loss

PRINCIPAL INVESTIGATOR: Gregory Beilman M.D.

CONTRACTING ORGANIZATION: Regents of the University of Minnesota
Minneapolis, MN 55455-2003

REPORT DATE: October 2015

TYPE OF REPORT:
Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2015		2. REPORT TYPE Annual		3. DATES COVERED 1Oct2014 - 30Sep2015	
4. TITLE AND SUBTITLE Hibernation-Based Therapy to Improve Survival of Severe Blood Loss				5a. CONTRACT NUMBER W81XWH-10-2-0121	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Gregory Beilman M.D., Kristine Muller M.S.; Sydne Muratore; Andrea Wolf E-Mail: beilm001@umn.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Regents of the University of Minnesota Minneapolis, MN 55455-2070				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The goals of this set experiments was to determine whether different concentrations of melatonin and DMSO along with 4M BHB would be as effective as our standard dosing regimen of 4M BHB/43mM Melatonin 20% DMSO. Based on the data presented data, our standard dosing regimen is the most effective treatment when compared to lower concentrations of melatonin DMSO in 4M BHB.					
15. SUBJECT TERMS Beta-hydroxybutyrate, melatonin					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 15	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Keywords.....	2
3. Overall Project Summary.....	3
4. Key Research Accomplishments.....	7
5. Conclusion.....	8
6. Publications, Abstracts, and Presentations.....	9
7. Inventions, Patents and Licenses.....	10
8. Reportable Outcomes.....	11
9. Other Achievements.....	12
10. References.....	13
11. Appendices.....	14

Introduction:

Blast injuries have been responsible for the majority of combat deaths in Iraq and Afghanistan, and the likelihood of being exposed to explosives is increasing for military personnel and civilians alike in war zones and other regions of political conflict. The injuries sustained are often accompanied by severe blood loss, and shock from this blood loss is the most common cause of potentially salvageable deaths from combat related injuries. D-beta hydroxybutyrate and melatonin (BHB/M) is a novel therapy designed to prolong survival in patients who are risk for bleeding to death. Our overall strategy in this series of studies is to use physiologic adaptive responses in hibernating mammals to aid in salvage of a patient with a potentially life-threatening blood loss, permitting survival to reach effective medical care. BHB/ M includes both an alternate fuel source for cells (D-beta hydroxybutyrate) and a powerful anti-oxidant, melatonin, to protect cells against damage. Our goal is to evaluate BHB/M in animal models of injury that simulate the battlefield casualty. Our previous work has shown increased survival for both rats and pigs treated with BHB/M. We wish to prove that BHB/M is a safe and effective therapy that can decrease mortality and improve outcomes for injured casualties suffering from polytrauma and blast injuries.

Key Words:

Beta-hydroxybutyrate

Melatonin

Poly-trauma

Resuscitation

Hemorrhage

Shock

Project Summary:


We were able to complete the experiments outlined in Table 1.

Table 1. Randomization table of lower concentration of melatonin/DMSO and standard concentration BHB

Drug Components	Animal Sex
LR	Male
4M BHB, 20mM Melatonin, 5% DMSO	Male
4M BHB, 10mM Melatonin, 5%DMSO	Female
LR	Male
4M BHB, 20mM Melatonin, 5%DMSO	Female
4M BHB, 10mM Melatonin, 5%DMSO	Male
4M BHB, 10mM Melatonin, 5%DMSO	Male
4M BHB, 20mM Melatonin, 5%DMSO	Male
4M BHB, 20mM Melatonin, 5%DMSO	Female
4M BHB, 10mM Melatonin, 5%DMSO	Female
4M BHB, 20mM Melatonin, 5%DMSO	Male
4M BHB, 10mM Melatonin, 5%DMSO	Female
4M BHB, 10mM Melatonin, 5%DMSO	Male
4M BHB, 20mM Melatonin, 5%DMSO	Female


All animals in this set of experiments had the same amount of blood removed and received the same amount of resuscitative fluids (Figure 1). Animals receiving lower concentrations of Melatonin and DMSO had slightly less fluid requirements. However, this trend was not statistically significant.

Figure 1. Hemorrhage and resuscitation requirements.



All animals receiving standard of care (n=2) or 4M BHB/20mM Melatonin, 5% DMSO (n=6) survived longer than those that were treated with 4M BHB/10mM Melatonin, 5% DMSO (Figure 2).

Figure 2. Kaplan Meier Curve for the observation of lower concentrations of Melatonin and DMSO.



Unsurprisingly, BHB concentrations were not statistically different between animals treated with 4M BHB and either 10mM Melatonin, 5% DMSO or 20mM Melatonin, 5% DMSO (Figure 3). Melatonin concentrations were not statistically significant between animals treated with 4M BHB and either 10mM Melatonin, 5% DMSO or 20mM Melatonin, 5% DMSO until FR160 and were back to baseline levels at FR 20 (Figure 4).

Figure 3. BHB concentrations in animals treated with lactated Ringers', 4M BHB with either 10mM Melatonin, 5% DMSO or 20mM Melatonin, 5% DMSO.





Figure 4. Melatonin concentrations in animals treated with lactated Ringers', 4M BHB with either 10mM Melatonin, 5% DMSO or 20mM Melatonin, 5% DMSO.



Key Research Accomplishments:

- Completed lower concentration melatonin/DMSO work
- Completed outlined grant work

Conclusion:

The goal of this set of experiments was to determine whether lower concentrations of melatonin and DMSO would be more effective as standard of care. Based on the data presented, animals treated with 4M BHB and either 10mM Melatonin/5% DMSO or 20mM Melatonin/5% DMSO showed no survival benefit when compared to standard of care (lactated Ringers'treatment).

Publications, Abstracts, and Presentations:

- A manuscript entitled “Safety of D-β-Hydroxybutyrate and Melatonin for the Treatment of Hemorrhagic Shock with Polytrauma” has been published at Shock.

Inventions, Patents and Licenses

- None

Reportable Outcomes:

- Working on obtaining NCE to complete final data analysis.

Other Achievements:

- None

References:

- None

Appendices:

Time points defined, Limited Resuscitation (LR)=maintenance of SBP above 80 mmHg, Full Resuscitation (FR)=maintenance of SBP above 90 mmHg, Hgb above 6 and Urine output > 1 cc/kg/hr.

Time point	Elapsed time from Baseline
Baseline	0
Shock 15	15 minutes
Shock 35	35 minutes
Shock 45	45 minutes
LR 30	30 minutes from the start of Limited Resuscitation phase, ~1.5 hours from baseline
LR 1	60 minutes from the start of Limited Resuscitation phase, ~2 hours from baseline
FR 1	1 hour from the start of Full Resuscitation, 2 hours from the start of Limited Resuscitation, ~3 hours from Baseline
FR 2	2 hour from the start of Full Resuscitation, 3 hours from the start of Limited Resuscitation, ~4 hours from Baseline
FR 160	160 minutes from the start of Full Resuscitation, 3 hours 40 minutes from the start of Limited Resuscitation, ~4.7 hours from Baseline
FR 170	170 minutes from the start of Full Resuscitation, 3 hours 50 minutes from the start of Limited Resuscitation, ~4.83 hours from Baseline
FR 3	3 hour from the start of Full Resuscitation, 4 hours from the start of Limited Resuscitation, ~5 hours from Baseline
FR 190	190 minutes from the start of Full Resuscitation, 4 hours 10 minutes from the start of Limited Resuscitation, ~5.2 hours from Baseline
FR 4	4 hour from the start of Full Resuscitation, 5 hours from the start of Limited Resuscitation, ~6 hours from Baseline
FR 5	5 hour from the start of Full Resuscitation, 6 hours from the start of Limited Resuscitation, ~7 hours from Baseline
FR 6	6 hour from the start of Full Resuscitation, 7 hours from the start of Limited Resuscitation, ~8 hours from Baseline
FR 7	7 hour from the start of Full Resuscitation, 8 hours from the start of Limited Resuscitation, ~9 hours from Baseline
FR 20	20 hour from the start of Full Resuscitation, 21 hours from the start of Limited Resuscitation, ~22 hours from Baseline